Leerink Partners analyst Puneet Souda maintained a Buy rating on Natera (NTRA – Research Report) on February 3 and set a price target of $200.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Puneet Souda’s rating is based on several promising developments for Natera, particularly in relation to its RhD test, which is part of the Panorama NIPT test. The company’s recent announcement that a major national payor, likely Aetna, has started reimbursing this test signals potential for broader adoption and increased revenue. While reimbursement from a single payor is not highly significant on its own, it reflects a positive trend for Natera to secure payments from more payors in the future.
Natera anticipates a substantial increase in revenue and average selling price (ASP) due to the RhD test. They project that broader commercial coverage could lead to significant financial gains, with potential outcomes ranging from $37.5 million to $151.8 million in additional revenue, depending on the ASP achieved. This suggests a strong upside for Natera, contributing to Souda’s Buy rating as the company capitalizes on these emerging opportunities in the healthcare sector.
In another report released on January 28, Goldman Sachs also maintained a Buy rating on the stock with a $190.00 price target.
Based on the recent corporate insider activity of 187 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of NTRA in relation to earlier this year.